TORINO, Italy I 03, 2024 I Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding ...

Despite a rough year, with a -65.45% YTD decline, Serina’s recent financing deal and innovative pipeline suggest that the company is poised for a comeback. Investors will be closely watching the ...

Sudo Biosciences has begun a Phase I trial of SUDO-550, a drug candidate designed to treat neuroinflammatory diseases.

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or ...

DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...

A collaborative research group, including researchers from Nagoya City University, National Institutes of Natural Sciences, ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

Dr. Lynn Kirkpatrick, CEO of Ensysce, was quoted, 'Overdose from prescription drugs is still a major societal issue and Ensysce may have the first opioid that can reduce deliberate and accidental ...

A study reveals that gut bacteria impact tamoxifen’s effectiveness in breast cancer treatment. Certain bacterial enzymes enhance the drug's recycling into the bloodstream, improving its efficacy.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate ...